Proton pump inhibitors and risk for Clostridium difficile associated diarrhea

Biomedical Journal

Volumn 37, Issue 4, 2014, Pages 178-183

  Biswal, Sasmita ^a  

^a VSS Medical College & Hospital   (India)

Author keywords

antibiotic; Clostridium difficile diarrhoea; proton pump inhibitors

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BILE SALT; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; FIDAXOMICIN; GLYCINE; METRONIDAZOLE; NITAZOXANIDE; PROTON PUMP INHIBITOR; QUINOLONE DERIVATIVE; RIFAXIMIN; TINIDAZOLE; VANCOMYCIN;

AGE; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIAL SURVIVAL; BACTERIAL TRANSMISSION; CAUSE OF DEATH; CDTB GENE; CHEMOTHERAPY; CHOLERA; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FOOD AND DRUG ADMINISTRATION; GENE; GENE EXPRESSION; HELICOBACTER PYLORI; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION CONTROL; INFECTION RISK; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; INTESTINE PERFORATION; KIDNEY FAILURE; MEDICAL ETHICS; MORBIDITY; NONHUMAN; PATHOGENESIS; PERNICIOUS ANEMIA; PSEUDOMEMBRANOUS COLITIS; REVIEW; RISK ASSESSMENT; SALMONELLOSIS; SINGLE DRUG DOSE; STOMACH PH; TCDA GENE; TCDB GENE; TOXIC MEGACOLON; ANIMAL; CLOSTRIDIUM INFECTION; COMPLICATION; CROSS INFECTION; DIARRHEA; PEPTOCLOSTRIDIUM DIFFICILE; RISK FACTOR;

ANIMALS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; DIARRHEA; HUMANS; PROTON PUMP INHIBITORS; RISK FACTORS;

EID: 84906220705     PISSN: 23194170     EISSN: None     Source Type: Journal    
DOI: 10.4103/2319-4170.128002     Document Type: Review

References (37)

1. Laine L, Ahnen D, McClain C, Solcia E, Walsh JH. Review article: Potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2000;14:651-68.
2. Thorens J, Froehlich F, Schwizer W, Saraga E, Bille J, Gyr K, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: A prospective randomised double blind study. Gut 1996;39:54-9.
3. Bavishi C, DuPont HL. Systematic Review: The use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther 2011;34:1269-81.
4. McCarthy DM. Adverse effects of proton pump inhibitor drugs: Clues and conclusions. Curr Opin Gastroenterol 2010;26:624-31.
5. Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010;170:784-90.
6. Cadle RM, Mansouri MD, Logan N, Kudva DR, Musher DM. Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. Am J Health Syst Pharm 2007;64:2359-63.
7. Rao A, Jump RL, Pultz NJ, Pultz MJ, Donskey CJ. In vitro killing of nosocomial pathogens by acid and acidified nitrite. Antimicrob Agents Chemother 2006;50:3901-4.
8. Poutanen SM, Simor AE. Clostridium difficile-associated diarrhea in adults. CMAJ 2004;171:51-8.
9. Bartlett JG, Perl TM. The new Clostridium difficile-what does it mean? N Engl J Med 2005;353:2503-5.
10. Kelly CP, LaMont JT. Clostridium difficile infection. Annu Rev Med 1998;49:375-90.
11. Bartlett JG. Clinical practice. Antibiotic -associated diarrhea. N Engl J Med 2002;346:334-9.
12. Pepin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile -Associated Diarrhoea: A Cohort Study during an epidemic in Quebes. Clin Infect Dis 2005;41:1254-60.
13. Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002;34:346-53.
14. Collins BJ, Crothers G, McFarland RJ, Love AH. Bile acid concentrations in the gastric juice of patients with erosive esophagitis. Gut 1985;26:495-6.
15. Sorg JA, Sonenshein AL. Bile salts and glycine as cogerminants for Clostridium difficile spores. J Bacteriol 2008;190:2505-12.
16. Deshpande A, Pant C, Pasupuleti V, Rolston DD, Jain A, Deshpande N, et al. Association between proton pump inhibitor therapy and clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol 2012;10:225-33.
17. Wilson KH, Sheagren JN, Freter R. Population dynamics of ingested Clostridium difficile in the gastrointestinal tract of the Syrian hamster. J Infect Dis 1985;151:355-61.
18. Archimandritis A, Souyioultzis S, Katsorida M, Tzivras M. Clostridium difficile colitis associated with a "triple" regimen, containing clarithromycin and metronidazole, to eradicate Helicobacter pylori. J Intern Med 1998;243:251-3.
19. Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 2002;136:834-44.
20. Ligumsky M, Lysy J, Siguencia G, Friedlander Y. Effect of long-term, continuous versus alternate-day omeprazole therapy on serum gastrin in patients treated for reflux esophagitis. J Clin Gastroenterol 2001;33:32-5.
21. Akhtar AJ, Shaheen M. Increasing incidence of Clostridium difficile-associated diarrhea in African-American and Hispanic patients: Association with the use of proton pump inhibitor therapy. J Natl Med Assoc 2007; 99:500-4.
22. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: Cohort and case-control studies. CMAJ 2004;171:33-8.
23. Eddi R, Malik MN, Shakov R, Baddoura WJ, Chandran C, Debari VA. Chronic kidney disease as a risk factor for Clostridium difficile infection. Nephrology 2010;15:471-5.
24. Bignardi GE. Risk for Clostridium difficile infection. J Hosp Infect 1998;40:1-15.
25. Rupnik M, Dupuy B, Fairweather NF, Gerding DN, Johnson S, Just I, et al. Revised nomenclature of Clostridium difficile toxins and associated genes. J Med Microbiol 2005;54:113-7.
26. Voth DE, Ballard JD. Clostridium difficile toxins: Mechanism of action and role in disease. Clin Microbiol Rev 2005;18:247-63.
27. Stewart DB, Hegarty JP. Correlation between virulence gene expression and proton pump inhibitors and ambient pH in Clostridium difficile: Results of an in vitro study. J Med Microbiol 2013;62:1517-23.
28. FDA Drug Safety Communication. Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). Rockville, MD: Food and Drug Administration; Feb 8 2012.
29. Mukherjee S. Diarrhea associated with lansoprazole. J Gastroenterol Hepatol 2003;18:602-3.
30. McVay CS, Rolfe RD. In vitro and in vivo activities of nitazoxanide against Clostridium difficile. Antimicrob Agents Chemother 2000;44:2254-8.
31. Citron DM, Tyrrell KL, Warren YA, Fernandez H, Merriam CV, Goldstein EJ. In vitro activities of tinidazole and metronidazole against Clostridium difficile, Prevotellabivia and Bacteroidesfragilis. Anaerobe 2005;11:315-7.
32. Gerber M, Ackermann G. OPT-80, a macrocyclic antimicrobial agent for the treatment of Clostridium difficile infections: A review. Expert Opin Investig Drugs 2008;17:547-53.
33. Kokkotou E, Moss AC, Michos A, Espinoza D, Cloud JW, Mustafa N, et al. Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters. Antimicrob Agents Chemother 2008;52:1121-6.
34. Kelly CP, Pothoulakins C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994;330:257-62.
35. Jump RL, Pultz MJ, Donskey CJ. Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with elevated pH. Antimicrob Agents Chemother 2007;51:2883-7.
36. Shah S, Lewis A, Leopold D, Dunstan F, Woodhouse K. Gastric acid suppression does not promote clostridial diarrhoea in the elderly. Q J Med 2000;93:175-81.
37. Loo VG, Fallone CA, DeSouza E, Lavallee J, Barkun AN. In vitro susceptibility of Helicobacter pylori to ampicillin, clarithromycin, metronidazole and omeprazole. J Antimicrob Chemother 1997;40:881-3.